Medlmmune and Tanabe Research Laboratories / Mitsui Tanabe Pharma Enter into Strategic Collaboration and Licensing Agreement for the Development of Pyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugates to Treat Cancer

Medlmmune and Tanabe Research Laboratories / Mitsui Tanabe Pharma Enter into Strategic Collaboration and Licensing Agreement for the Development of Pyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugates to Treat Cancer

San Diego, CA /Osaka, JPN/Gaithersburg, MD September 23, 2015 – MedImmune, the global biologics research and development arm of AstraZeneca, and Tanabe Research Laboratories U.S.A., Inc. (TRL), a subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC), today announced that they have entered into a strategic collaboration and licensing agreement under which TRL will use MedImmune’s pyrrolobenzodiazepine […]

Read More »
Covagen and Tanabe Research Laboratories Expand Strategic Research Collaboration for Development of Bispecific FynomAbs

Covagen and Tanabe Research Laboratories Expand Strategic Research Collaboration for Development of Bispecific FynomAbs

Tanabe Research Laboratories and Mitsubishi Tanabe Pharma Nominate First Bispecific FynomAb® for Preclinical Development and Exercise an Option for a Second Bispecific FynomAb Program ZURICH-SCHLIEREN, Switzerland and SAN DIEGO, Nov. 21, 2013 – Covagen and Tanabe Research Laboratories U.S.A, Inc. (TRL), a fully owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC), today announced that they […]

Read More »
Tanabe Research Laboratories USA Inc. and Mitsubishi Tanabe enter into a strategic collaboration and license agreement with Covagen for the development of bispecific FynomAbs

Tanabe Research Laboratories USA Inc. and Mitsubishi Tanabe enter into a strategic collaboration and license agreement with Covagen for the development of bispecific FynomAbs

Tanabe Research Laboratories U.S.A. Inc. (TRL) and its parent company Mitsubishi Tanabe Pharma Corporation (Osaka, Japan) have entered into a strategic research collaboration and license agreement with Covagen of Zurich Switzerland. Under the agreement, Covagen will use Covagen’s proprietary Fynomer-antibody platform to generate bispecific proteins (FynomAbs) against two target pairs selected by TRL and Mitsubishi […]

Read More »